Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 9/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.49 |
| ▸ | TSLP | Q969D9 | 4/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.48 |
| ▸ | SHH | Q15465 | 1/20 | 0.48 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.46 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | MC5R | P33032 | 1/20 | 0.45 |
| ▸ | MC3R | P41968 | 1/20 | 0.45 |
| ▸ | MC1R | Q01726 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26422370 | 1.00 | SSTR2 (0.49) | SSTR2SSTR5TSLPSSTR4EPHA2 | |
| SCHEMBL23417726 | 0.95 | SSTR2 (0.52) | SSTR2SSTR5TSLPSSTR4EPHA2 | |
| SCHEMBL23417758 | 0.93 | SSTR2 (0.55) | SSTR2SSTR5TSLPSSTR4EPHA2 | |
| SCHEMBL23417755 | 0.93 | SSTR2 (0.50) | SSTR2SSTR5TSLPSSTR4EPHA2 | |
| SCHEMBL23417794 | 0.92 | SSTR2 (0.51) | SSTR2SSTR5TSLPSSTR4EPHA2 | |
| SCHEMBL26428235 | 0.92 | SSTR2 (0.50) | SSTR2SSTR5TSLPSSTR4EPHA2 | |
| SCHEMBL29343629 | 0.92 | SSTR2 (0.51) | SSTR2SSTR5TSLPSSTR4EPHA2 | |
| SCHEMBL26418148 | 0.91 | SSTR2 (0.51) | SSTR2SSTR5TSLPSSTR4EPHA2 | |
| SCHEMBL23417835 | 0.90 | TSLP (0.49) | SSTR2SSTR5TSLPSSTR4EPHA2 | |
| SCHEMBL24668370 | 0.90 | SSTR2 (0.54) | SSTR2SSTR5TSLPSSTR4EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | SSTR2 3356/4885SSTR5 2125/4885TSLP 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.